

NineBiopharm Co., Ltd.

| Category | Enterprise Creation | | | | | | | | | | | | | | | | | | |
|--|--|-------------------|-----------------------------------|----------------|-------------------------------|-------------|-------------------------------|---------------------------|-------------------|----------------|----------------------|--|--|-------------|------------------|------------------------|----------------|--|------------|
| ○ Corporation (Preliminary Enterprise) | NineBiopharm Co., Ltd. | | | | | | | | | | | | | | | | | | |
| ○ Representative | Jae-Duck Ryoo | | | | | | | | | | | | | | | | | | |
| ○ Establishment year | 03/02/2015 | | | | | | | | | | | | | | | | | | |
| ○ Specialized Field | Bio-New Material Development, Peptidomimetic Material Development | | | | | | | | | | | | | | | | | | |
| ○ Address | 125, Osongsangmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea | | | | | | | | | | | | | | | | | | |
| ○ Home page | - Homepage: | | | | | | | | | | | | | | | | | | |
| ○ Enterprise Brief Introduction | NineBiopharm Co., Ltd. is a company that focuses on identifying noble biomaterials with its proprietary ARisT (Advanced Remodeling in silico Technology), a remodeling platform that can maximize targeting, sustainability, activity, and commercialization of materials based on in-silico technology designed to increase efficiency and reduce cost significantly vs. the conventional drug development platform HTS(High-throughput screening). | | | | | | | | | | | | | | | | | | |
| ○ Product and Pipeline Introduction | <table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td rowspan="3" style="text-align: center; vertical-align: middle;">- Medical devices</td> <td>Filler(injectable dermal fillers)</td> </tr> <tr> <td>Wound dressing</td> </tr> <tr> <td>Body filler(Lipolytic filler)</td> </tr> <tr> <td rowspan="7" style="text-align: center; vertical-align: middle;">- Medicines</td> <td>CPP(Cell Penetrating Peptide)</td> </tr> <tr> <td>Osteoarthritis medication</td> </tr> <tr> <td>Obesity treatment</td> </tr> <tr> <td>Acne treatment</td> </tr> <tr> <td>Anti-microbial cream</td> </tr> <tr> <td>Psoriasis treatment, Atopic dermatitis</td> </tr> <tr> <td>Hair loss prevention and hair regrowth</td> </tr> <tr> <td rowspan="3" style="text-align: center; vertical-align: middle;">- Cosmetics</td> <td>Anti-cancer drug</td> </tr> <tr> <td>Anti-wrinkle/whitening</td> </tr> <tr> <td>Anti-pollution</td> </tr> <tr> <td></td> <td>Acne cream</td> </tr> </tbody> </table> | - Medical devices | Filler(injectable dermal fillers) | Wound dressing | Body filler(Lipolytic filler) | - Medicines | CPP(Cell Penetrating Peptide) | Osteoarthritis medication | Obesity treatment | Acne treatment | Anti-microbial cream | Psoriasis treatment, Atopic dermatitis | Hair loss prevention and hair regrowth | - Cosmetics | Anti-cancer drug | Anti-wrinkle/whitening | Anti-pollution | | Acne cream |
| - Medical devices | Filler(injectable dermal fillers) | | | | | | | | | | | | | | | | | | |
| | Wound dressing | | | | | | | | | | | | | | | | | | |
| | Body filler(Lipolytic filler) | | | | | | | | | | | | | | | | | | |
| - Medicines | CPP(Cell Penetrating Peptide) | | | | | | | | | | | | | | | | | | |
| | Osteoarthritis medication | | | | | | | | | | | | | | | | | | |
| | Obesity treatment | | | | | | | | | | | | | | | | | | |
| | Acne treatment | | | | | | | | | | | | | | | | | | |
| | Anti-microbial cream | | | | | | | | | | | | | | | | | | |
| | Psoriasis treatment, Atopic dermatitis | | | | | | | | | | | | | | | | | | |
| | Hair loss prevention and hair regrowth | | | | | | | | | | | | | | | | | | |
| - Cosmetics | Anti-cancer drug | | | | | | | | | | | | | | | | | | |
| | Anti-wrinkle/whitening | | | | | | | | | | | | | | | | | | |
| | Anti-pollution | | | | | | | | | | | | | | | | | | |
| | Acne cream | | | | | | | | | | | | | | | | | | |
| ○ Patent and Certification, Licensing, Thesis, Investment status, etc. | <ul style="list-style-type: none"> - 11 patents applied or registered - 2020 R&D fund from Ministry of Health and Welfare's R&D project: KRW 2.1 billion - Series A financing: investment firm KRW 2.5 billion | | | | | | | | | | | | | | | | | | |